Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2ZP0A
|
|||
| Drug Name |
Donanemab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Amyloid beta A4 protein (APP) | Target Info | . | [2] |
| Amyloid beta A4 protein (APP) | Target Info | . | [3] | |
| KEGG Pathway | Notch signaling pathway | |||
| Alzheimer's disease | ||||
| Reactome | Nuclear signaling by ERBB4 | |||
| Degradation of the extracellular matrix | ||||
| Regulated proteolysis of p75NTR | ||||
| NRIF signals cell death from the nucleus | ||||
| Activated NOTCH1 Transmits Signal to the Nucleus | ||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | ||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | ||||
| EPH-ephrin mediated repulsion of cells | ||||
| WikiPathways | Notch Signaling Pathway | |||
| Signaling by ERBB4 | ||||
| Signaling by NOTCH3 | ||||
| Signaling by NOTCH4 | ||||
| Signaling by NOTCH1 | ||||
| Signaling by NOTCH2 | ||||
| Notch Signaling Pathway | ||||
| Alzheimers Disease | ||||
| Signalling by NGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05108922) A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704. | |||
| REF 3 | 'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings. J Prev Alzheimers Dis. 2023;10(3):595-599. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.